AIM: To analyze the effect of compound xuesaitong combined with conbercept on central macular retinal thickness(CMT), fluorescein fundus angiography and best corrected visual acuity(BCVA)in pathological patients with choroidal neovascularization(CNV).

METHODS:A total of 60 cases(60 eyes)with pathological myopia and CNV who were admitted to our hospital during January to October 2016 were enrolled in the study. They were divided into observation group and control group, 30 cases in each group. Observation group was treated with compound xuesaitong combined with conbercept. Control group was treated with conbercept only. Changes of CMT, intraocular pressure(IOP), area of CNV, BCVA and serum vascular endothelial growth factor(VEGF)before surgery, 4 and 12wk after surgery were compared. Complications during follow-up were statistically analyzed.

RESULTS: At 12wk after surgery, the total effective rate was 97% in observation group, 80% in control group and the difference was significant(P<0.01). The CMT, IOP, area of CNV and serum VEGF levels were significantly lower or smaller than those before surgery while BCVA was significantly higher than that before surgery(P<0.01). There were no local complications of systematic severe complications.

CONCLUSION: Compound xuesaitong combined with conbercept can effectively reduce CMT and IOP, reduce the area of CNV and significantly improve visual acuity. Its anti-VEGF effect is obvious, safe and feasible.